Estrogen Receptor β as a Pharmaceutical Target

Research output: Contribution to journalReview articlepeer-review

61 Scopus citations

Abstract

A major issue in clinical endocrinology today is how to use hormones to achieve the health benefits that they clearly can provide but avoid the negative side effects, that is, how to develop more precise medicines. This problem of how to use hormones is pervasive in clinical endocrinology. It is true for estrogen, progesterone, androgen, vitamin D, and thyroid hormone, and the problem is amplified in the case of new ligands for the more recently discovered nuclear receptors. Selective targeting of hormone receptor subtypes is one attractive way to harness the beneficial effects of hormones while reducing unwanted side effects. Here, we focus on estrogen receptor (ER)β, which has promise as a selective target in hormone replacement therapy, and in breast and prostate cancers.

Original languageEnglish (US)
Pages (from-to)92-99
Number of pages8
JournalTrends in Pharmacological Sciences
Volume38
Issue number1
DOIs
StatePublished - Jan 1 2017

ASJC Scopus subject areas

  • Toxicology
  • Pharmacology

Fingerprint

Dive into the research topics of 'Estrogen Receptor β as a Pharmaceutical Target'. Together they form a unique fingerprint.

Cite this